{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:17:53Z","timestamp":1781223473402,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Cariprazine is a third-generation antipsychotic medication approved for the treatment of schizophrenia and bipolar disorder, with unique pharmacodynamic and pharmacokinetic properties. In this case series, the functional and symptomatic improvement of three patients who had been diagnosed with different psychiatric disorders and who exhibited various symptoms from psychotic to mood symptoms is described. The first case is about a young male patient with bipolar disorder and cocaine abuse who managed to become abstinent from cariprazine. The second and third cases describe patients with psychosis suffering from positive, cognitive and mood symptoms who were non-adherent to previous medication. In both cases, cariprazine was well-tolerated and effective in alleviating symptoms, thus improving their everyday functioning as well. In the discussion, the associations between symptom domains and the receptor profile of cariprazine are also highlighted, providing an explanation of the observed effects. It is concluded that cariprazine is a good treatment option for patients with symptoms of psychosis and addiction; is well-tolerated without the induction of side effects such as weight gain or sedation; and is appropriate for patients who have problems with adherence.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.878889","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T16:28:43Z","timestamp":1659371323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series"],"prefix":"10.3389","volume":"13","author":[{"given":"Tommaso","family":"Vannucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Taddeucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D 3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.","volume":"59","author":"Gyerty\u00e1n","year":"2011","journal-title":"Neurochem Int."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, A D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics.","author":"Kiss","year":"2012","journal-title":"Schizophr Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists - Aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.","volume":"69","author":"Citrome","year":"2015","journal-title":"Int J Clin Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/NDT.S159704","article-title":"Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.","volume":"14","author":"Citrome","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B6","year":"","journal-title":"Reagila Summary of Product Characteristics [Internet]."},{"key":"B7","author":"Gedeon Richter","year":"2021"},{"key":"B8","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development.","volume":"7","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep."},{"key":"B9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study.","volume":"176","author":"Earley","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression.","volume":"173","author":"Durgam","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","article-title":"Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies.","volume":"25","author":"Mcintyre","year":"2019","journal-title":"CNS Spectr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes.","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.2174\/1381612822666160701084447","article-title":"The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders.","volume":"22","author":"De Berardis","year":"2016","journal-title":"Curr Pharm Des."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.1073\/pnas.89.17.8155","article-title":"Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.","volume":"89","author":"Levesque","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.803208","article-title":"Reducing addiction in bipolar disorder via hacking the dopaminergic system.","volume":"12","author":"Grunze","year":"2021","journal-title":"Front Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-012-2906-7","article-title":"Cariprazine (RGH-188), a D3-preferring dopamine D 3\/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.","volume":"226","author":"Rom\u00e1n","year":"2013","journal-title":"Psychopharmacology (Berl)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007952","article-title":"Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice.","volume":"4","author":"Doly","year":"2009","journal-title":"PLoS One."},{"key":"B18","first-page":"10","article-title":"Cariprazine may decrease substance abuse in patients with bipolar I disorder.","volume":"36","author":"Sanders","year":"2019","journal-title":"Psychiatr Times."},{"key":"B19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report.","volume":"40","author":"Ricci","year":"2021","journal-title":"J Addict Dis."},{"key":"B20","year":"2018","journal-title":"Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder [Internet]."},{"key":"B21","year":"2021","journal-title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial.","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II\/III studies.","volume":"29","author":"Marder","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase ii\/iii studies.","volume":"17","author":"Barab\u00e1ssy","year":"2021","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.868751","article-title":"Cariprazine\u2019s potential in improving social dysfunction in patients with schizophrenia: a perspective.","volume":"13","author":"Morozov","year":"2022","journal-title":"Front Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/03007995.2021.1932446","article-title":"The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial.","volume":"37","author":"Vieta","year":"2021","journal-title":"Curr Med Res Opin."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.878889\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T16:28:52Z","timestamp":1659371332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.878889\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":30,"alternative-id":["10.3389\/fpsyt.2022.878889"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.878889","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"878889"}}